Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire, a specialty biopharmaceutical company, has launched Vyvanse for the treatment of adults with attention deficit hyperactivity disorder.
Subscribe to our email newsletter
This launch follows the recent FDA approval of Vyvanse to treat attention deficit hyperactivity disorder (ADHD) in the adult population. Vyvanse is now available in US pharmacies nationwide in six once-daily dosage strengths.
Shire received approval in April 2008 from the FDA for Vyvanse for the treatment of ADHD in adults aged 18 to 55 years. Vyvanse is available in six dosage strengths of 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg.
To raise awareness of ADHD in adults and recognize the launch of Vyvanse for adults, Shire has also partnered with celebrity designer Ty Pennington to shine the spotlight on living as an adult with ADHD.